Paris, France – Abivax, a clinical stage biotech company, appoints Antonino Ligresti and Dominique Costantini to its board of directors. [break]
Dr. Ligresti has extensive experience in the healthcare field and in market access issues. He is a medical doctor and surgeon, specialized in internal medicine and cardiology. He began his career at the medical clinic of the University of Milan, and later moved to the Fatebenefratelli Hospital, also in Milan.
In 1979, he created the first private hospital group in Italy, recognized for the quality of medical care it provided, as well as for its research and teaching collaboration with universities. He sold the group in 2000.
Dr. Costantini, a senior executive and CEO, is a medical doctor with a degree in immunology from Necker Paris V, has more than 20 years of experience in the pharma/biotech industry including key positions at HMR (now Sanofi) across a number of functions and business units.
She is the co - September 16, 2015, Paris, France – Abivax, a clinical stage biotech company, appoints Antonino Ligresti and Dominique Costantini to its board of directors.
Article continues below
]
Dr. Ligresti has extensive experience in the healthcare field and in market access issues. He is a medical doctor and surgeon, specialized in internal medicine and cardiology. He began his career at the medical clinic of the University of Milan, and later moved to the Fatebenefratelli Hospital, also in Milan.
In 1979, he created the first private hospital group in Italy, recognized for the quality of medical care it provided, as well as for its research and teaching collaboration with universities. He sold the group in 2000.
Dr. Costantini, a senior executive and CEO, is a medical doctor with a degree in immunology from Necker Paris V, has more than 20 years of experience in the pharma/biotech industry including key positions at HMR (now Sanofi) across a number of functions and business units.
She is the co-founder and CEO of OSE Pharma (listed on Euronext Paris in 2015), an innovative company focused on therapeutic vaccines to treat cancer.
Prior to OSE Pharma, Dr. Costantini founded Onxeo (originally named BioAlliance Pharma) in 1997, a company focused on oncology and supportive care with drug delivery technologies. She took the company public in 2005, and was CEO until 2011. ■
LATEST MOVES FROM Paris, France – Abivax, a clinical stage biotech company, appoints Antonino Ligresti and Dominique Costantini to its board of directors. [break]
Dr. Ligresti has extensive experience in the healthcare field and in market access issues. He is a medical doctor and surgeon, specialized in internal medicine and cardiology. He began his career a